US · SNDL
SNDL Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Calgary, AB T2R 1P3
- Website
- sndlgroup.com
Price · as of 2024-12-31
$1.41
Market cap 396.55M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $16.50 | +1,070.21% |
| Intrinsic Value(DCF) | $2.50 | +77.3% |
| Graham-Dodd Method(GD) | $1.40 | -0.71% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $13.30 | $285.48 | $5,812,507.06 | $0.00 | $0.00 |
| 2020 | $14.20 | $15.49 | $0.00 | $0.00 | $0.00 |
| 2021 | $4.75 | $17.50 | $3.66 | $0.50 | $0.00 |
| 2022 | $1.56 | $112.94 | $23.96 | $0.00 | $0.00 |
| 2023 | $1.36 | $17.43 | $16.50 | $0.60 | $0.00 |
| 2024 | $1.56 | $23.12 | $16.32 | $1.40 | $0.00 |
AI valuation
Our deep-learning model estimates SNDL Inc.'s (SNDL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $16.50
- Current price
- $1.41
- AI upside
- +1,070.21%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.50
+77.3% upside
Graham-Dodd
$1.40
-0.71% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SNDL | SNDL Inc. | $1.41 | 396.55M | +1,540% | +77% | -1% | — | -5.99 | 0.51 | 0.63 | -11.63 | — | 0.61 | 26.11% | -11.28% | -10.30% | -8.20% | -8.54% | -6.82% | 0.13 | -13.49 | 5.10 | 3.06 | 1.60 | -4162.00% | 126.00% | -27858.00% | 7.62% | 0.61 | 3.96% | 0.00% | 0.00% | 8.92% | -4.62 | 10.92 | 0.52 | 0.99 |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | 347.63M | +2,616% | +600% | — | — | -60.62 | 9.94 | 1.37 | -56.76 | — | -12.26 | 83.29% | 9.95% | -2.26% | 64.49% | -72.80% | -1.79% | 0.00 | 0.97 | 1.13 | 1.42 | 75.38 | -9370.00% | 4746.00% | -26637.00% | 20.89% | 0.42 | -209.73% | 0.00% | 0.00% | 99.29% | 5.92 | 2.06 | 0.59 | -4.79 |
| AQST | Aquestive Therapeutics, I… | $4.00 | 397.23M | +466% | -73% | — | — | -5.21 | -3.82 | 3.99 | -7.37 | -1.78 | -3.82 | 68.95% | -53.46% | -76.68% | 52.97% | 32.25% | -55.57% | -0.63 | -1.83 | 4.68 | 4.18 | 1.26 | 29231.00% | 1380.00% | 38702.00% | -15.63% | -1.90 | 37.66% | 0.00% | 0.00% | 18.71% | -6.38 | -5.46 | 3.41 | -3.77 |
| CMPS | COMPASS Pathways plc | $6.90 | 662.41M | — | — | — | — | -1.63 | 1.63 | — | -0.80 | — | 1.63 | 0.00% | — | — | -81.55% | -590.05% | -63.36% | 0.21 | -39.79 | 5.92 | 5.49 | 0.89 | -86.00% | — | 2231.00% | -47.22% | -3.50 | -394.64% | 0.00% | 0.00% | 0.00% | -0.67 | -1.00 | — | -2.75 |
| CRVS | Corvus Pharmaceuticals, I… | $18.26 | 1.53B | — | — | — | — | -4.52 | 8.65 | — | -8.41 | -5.57 | 8.65 | 0.00% | — | — | -174.85% | 1026.95% | -108.85% | 0.03 | — | 1.54 | 1.47 | 0.28 | 8124.00% | — | 607.00% | -9.02% | -0.72 | 947.77% | 0.00% | 0.00% | 0.00% | -8.38 | -9.08 | — | -4.40 |
| EBS | Emergent BioSolutions Inc… | $8.15 | 434.81M | +481% | -56% | +80% | — | 9.14 | 0.92 | 0.65 | 3.56 | — | 5.59 | 48.62% | 13.47% | 7.08% | 10.46% | 6.53% | 3.88% | 1.09 | 1.69 | 5.01 | 2.19 | 1.54 | -12583.00% | -2881.00% | 33799.00% | 32.60% | 1.29 | 16.09% | 0.00% | 0.00% | 48.82% | 8.47 | 5.41 | 1.14 | 1.49 |
| EOLS | Evolus, Inc. | $4.30 | 278.73M | +754% | +521% | — | — | -16.70 | 152.52 | 3.16 | -35.41 | — | -13.07 | 68.46% | -12.92% | -18.94% | 664.86% | -75.16% | -23.92% | 23.54 | -1.84 | 2.40 | 2.14 | -1.72 | -2500.00% | 3176.00% | -4536.00% | -2.31% | -0.29 | -42.53% | 0.00% | 0.00% | 2.46% | -25.72 | -45.46 | 3.32 | -0.33 |
| ESPR | Esperion Therapeutics, In… | $3.35 | 661.73M | +1,302% | +27,124% | — | — | -6.11 | -0.81 | 0.95 | 100.78 | — | -0.81 | 79.36% | 16.37% | -15.57% | 12.27% | 177.11% | -18.83% | -1.52 | 0.92 | 1.37 | 0.91 | 58.98 | -8621.00% | 18566.00% | -8231.00% | -7.58% | -0.10 | -78.04% | 0.00% | 0.00% | 3.87% | 14.02 | -31.82 | 2.30 | -4.45 |
| OLMA | Olema Pharmaceuticals, In… | $24.20 | 1.9B | — | — | — | — | -2.09 | 0.66 | — | 1.14 | -74.60 | 0.66 | 0.00% | — | — | -39.07% | 974.77% | -35.57% | 0.00 | — | 10.50 | 10.45 | 0.97 | 280.00% | — | 2482.00% | -38.59% | -2.50 | 716.12% | 0.00% | 0.00% | 26.56% | 1.14 | 1.55 | — | 2.53 |
| ORGO | Organogenesis Holdings In… | $3.21 | 407.39M | +1,529% | +5,869% | -5% | +241% | 10.27 | 1.27 | 0.67 | 5.43 | — | 1.45 | 73.57% | 7.92% | 10.09% | 10.81% | 15.37% | 6.75% | 0.27 | 19.59 | 3.62 | 3.11 | -0.17 | -160000.00% | 1704.00% | -68573.00% | -6.43% | -0.10 | -8.41% | 2.99% | 30.70% | 2.99% | 8.25 | -15.07 | 0.65 | 3.09 |
| SIGA | SIGA Technologies, Inc. | $6.47 | 463.33M | +352% | -48% | — | -5% | 6.20 | 1.70 | 2.65 | 3.01 | — | 1.71 | 77.44% | 50.45% | 42.69% | 28.70% | 100.67% | 23.75% | 0.00 | — | 9.12 | 6.97 | -2.20 | -1263.00% | -86.00% | -4860.00% | 13.27% | 1.92 | 90.03% | 11.62% | 72.10% | 13.06% | 3.03 | 4.36 | 1.53 | 10.11 |
About SNDL Inc.
SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use markets; and private sale of recreational cannabis through corporate owned and franchised retail cannabis stores. The company also produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
- CEO
- Zachary Ryan George
- Employees
- 2.6K
- Beta
- 0.73
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.50 ÷ $1.41) − 1 = +77.3% (DCF, example).